Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again.
Two influential advisory firms, Institutional Shareholder Services and Glass Lewis, are rallying investors to vote against AZ’s 2024 pay proposal for Soriot at the company’s annual general meeting later this month.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,